A federal bankruptcy judge announced on Friday his intention to approve Purdue Pharma’s new agreement aimed at addressing thousands of lawsuits related to opioid-related costs. This deal also includes financial support for victims affected by the opioid crisis.
The agreement, managed by U.S. Bankruptcy Judge Sean Lane, mandates that the Sackler family, which owns Purdue, will contribute up to $7 billion and will have to give up ownership of the company. This new proposal is replacing a prior agreement that was deemed insufficient by the U.S. Supreme Court last year since it didn’t properly protect family members from future lawsuits. The judge is set to provide further details at a hearing on Tuesday.
This settlement represents one of the largest in ongoing opioid litigation involving state and local governments. The total value of these settlements has approached around $50 billion. If finalized, it could signify the end of a long and turbulent chapter in the ongoing pursuit of accountability for Purdue’s involvement in the opioid crisis, which has claimed around 900,000 lives in the U.S. since 1999, including fatalities from heroin and illegal fentanyl.
Legal professionals have characterized this situation as one of the most complicated bankruptcies in U.S. history. Ultimately, attorneys representing a wide range of stakeholders—including Purdue, various municipalities, Native American tribes, and affected individuals—largely supported the bankruptcy plan that Purdue initiated six years ago while facing lawsuits with claims potentially reaching trillions of dollars.
“I mean, if we could somehow come up with $40 trillion or maybe even $100 trillion to compensate everyone affected, that would be great,” Purdue’s attorney Marshall Huebner remarked. “But given that it’s not feasible, I believe this plan is legitimate and provides the most benefit to the most people as quickly as possible.”
The opposition parties are pretty quiet this time.
The recent developments stirred emotional discussions and highlighted the ongoing contentious debates among various groups that have pursued Purdue in court, exposing the tension between the quest for justice and the realities of bankruptcy proceedings.
The U.S. Supreme Court had previously rejected another settlement, ruling that it was wrong to grant the Sackler family immunity from potential lawsuits tied to opioids. Under the new terms, entities that oppose the settlement will still have the option to file lawsuits. The Sackler family reportedly has considerable assets, much of it held in offshore trusts that are challenging to access through litigation.
This time, however, government entities involved seem to have reached a more comprehensive agreement, and opposition from affected individuals has not been as vocal. When over 54,000 personal injury victims were asked to vote on the proposed plan, only 218 opposed it, and many didn’t cast a vote at all.
In contrast to previous cases, there were no significant protests outside the courthouse. A handful of dissenters spoke during the proceedings, some even interrupting the judge at times. A few argued that the settlement money should solely go to victims, not to government bodies. Lane indicated that such matters were beyond the bankruptcy court’s jurisdiction, although he noted that prosecutors could still pursue the Sacklers criminally.
At Thursday’s hearing, a Florida woman expressed her struggles with addiction following her husband’s prescription of OxyContin after an accident, asserting that the agreement fell short.
“It’s only fair that the Sacklers and Purdue Pharmaceuticals face the consequences of their actions,” Pamela Bartz Harashak said in a video presentation.
Agreement would be the largest opioid settlement
The multitude of lawsuits against Purdue and other pharmaceutical companies, drug distributors, and pharmacy chains kicked off roughly a decade ago.
Many of the significant lawsuits are already resolved, accumulating close to $50 billion, primarily directed toward combatting the opioid crisis. However, there’s no established mechanism to monitor the allocation of these funds or evaluate their effectiveness, raising concerns regarding transparency and accountability.
As for the Purdue deal, it stands to be one of the largest settlements yet. The Sackler family will contribute up to $7 billion and surrender ownership of the company, which hasn’t had directorship or received payments since 2018. A similar court hearing occurred four years ago, but this week’s session did not see testimonies from witnesses.
In an effort to distance itself from its past, Purdue plans to change its name to Qunoor Pharma and appoint a new overseer who will focus future earnings on alleviating the opioid crisis. This transition is projected for the spring of 2026.
The settlement will include several non-financial aspects as well. Certain Sackler family members must disengage from businesses that market opioids internationally. Additionally, the family will be barred from having their names associated with institutions that receive charitable contributions—a move already seen in some museums and universities.
Lastly, company-related documents, including those typically protected under attorney-client privilege, will be made accessible to the public.
